How PATH and a state-owned vaccine manufacturer are teaming up to protect Vietnam from seasonal and pandemic influenza
It takes 22 days to produce an influenza vaccine through a series of carefully choreographed steps under precise environmental conditions.
It also takes chickens. Lots of chickens.
Today, the world is several billion doses short of being able to produce enough influenza vaccine to protect the global population in a pandemic. PATH is working side by side with vaccine manufacturers in Vietnam, Brazil, China, India, and Serbia to boost their capacity to produce vaccines against both seasonal and pandemic influenza that meet international standards.
In Vietnam, PATH’s long-standing partnership with the Vietnamese government and the state-owned Institute of Vaccines and Medical Biologicals (IVAC) paved the way for Vietnam’s first fully operational, industrial-scale vaccine production facility and successful clinical trials of influenza vaccine candidates that soon could be licensed for use.
From helping IVAC ready a state-of-the-art production facility to procuring more than 5,000 live chickens to produce the eggs needed for vaccine manufacturing, PATH has provided critical support to help Vietnam meet its own vaccine needs.
The work builds on earlier support for IVAC from the World Health Organization and is funded by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority.